Efavirenz/Emtricitabine/Tenofovir and Posaconazole Interaction

Understanding the Efavirenz/Emtricitabine/Tenofovir and Posaconazole Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Efavirenz/Emtricitabine/Tenofovir belongs to the NNRTI / NRTI Combination class and Posaconazole belongs to the Azole Antifungal class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Efavirenz causes the body to break down posaconazole more quickly, which lowers the amount of medicine available to fight infections. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Efavirenz/Emtricitabine/Tenofovir has 32 total documented interactions on file in this dataset, and Posaconazole has 27. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Avoid using these drugs together unless your doctor decides the benefits are greater than the risks. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Efavirenz/Emtricitabine/Tenofovir or Posaconazole based on a web page, speak with your prescriber or pharmacist before making any change.